The U.S. Food and Drug Administration (FDA) has approved the immunotherapy Tecentriq (atezolizumab), in combination with Cotellic (cobimetinib) and Zelboraf (vemurafenib), for the treatment of BRAF V600 mutation-positive advanced melanoma. The decision comes after promising findings from IMSPIRE150 (NCT02908672), a Phase 3 trial in which the triple combination significantly extended the time patients lived without signs of disease progression, compared with a combination of Cotellic and Zelboraf. “Today’s FDA approval of this Tecentriq combination represents an…
You must be logged in to read/download the full post.
The post FDA Approves Tecentriq Combo for Certain Advanced Melanomas appeared first on BioNewsFeeds.